Clinical significance of GSTM1 and GSTT1 polymorphisms in younger patients with acute myeloid leukemia of intermediate-risk cytogenetics.
We investigated the association between GSTM1 or GSTT1 polymorphisms and clinical outcomes in 133 younger patients with AML of intermediate-risk cytogenetics. Clinical outcomes were not significantly different among the GSTM1 polymorphism genotypes, whereas cumulative incidence of relapse (CIR) was significantly lower and event-free survival (EFS) was significantly higher in patients with the GSTT1-present genotype compared with those with the GSTT1-null genotype (CIR at 5 year, 28.9% vs. 44.6%, P=0.018; EFS at 5 year, 51.4% vs. 34.1%, P=0.029). Our results suggest that GSTT1 gene polymorphism has significant clinical implications in younger patients with AML of intermediate-risk cytogenetics.
Lee
Ho Sup
HS
Department of Internal Medicine, Kosin University Gospel Hospital, Busan, Republic of Korea.
Lee
Je-Hwan
JH
Hur
Eun-Hye
EH
Lee
Michael Jinpyo
MJ
Lee
Jung-Hee
JH
Kim
Dae-Young
DY
Kim
Se Hyung
SH
Seol
Miee
M
Kang
Sol-Ip
SI
Ryu
Seong-Gil
SG
Kang
Young-Ah
YA
Lee
Young-Shin
YS
Kang
Mun Jung
MJ
Seo
Eul-Ju
EJ
Kim
Yang Soo
YS
Chi
Hyun Sook
HS
Park
Chan Jeoung
CJ
Jang
Seongsoo
S
Yun
Sung-Cheol
SC
Lee
Kyoo-Hyung
KH